PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
1067.86%
Positive EBIT growth while AGEN is negative. John Neff might see a substantial edge in operational management.
39.05%
Positive operating income growth while AGEN is negative. John Neff might view this as a competitive edge in operations.
24.67%
Positive net income growth while AGEN is negative. John Neff might see a big relative performance advantage.
25.26%
EPS growth of 25.26% while AGEN is zero. Bruce Berkowitz would see if minimal gains can accelerate over time.
25.26%
Diluted EPS growth of 25.26% while AGEN is zero. Bruce Berkowitz would see if minimal gains can be scaled further for a bigger lead.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-25.67%
Both companies show negative OCF growth. Martin Whitman would analyze broader economic or industry conditions limiting cash flow.
-25.67%
Both companies show negative FCF growth. Martin Whitman would consider an industry-wide capital spending surge or margin compression.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-10.29%
Negative 10Y OCF/share CAGR while AGEN stands at 89.70%. Joel Greenblatt would scrutinize managerial effectiveness and product competitiveness.
-10.29%
Negative 5Y OCF/share CAGR while AGEN is at 84.10%. Joel Greenblatt would question the firm’s operational model or cost structure.
-46.03%
Negative 3Y OCF/share CAGR while AGEN stands at 60.25%. Joel Greenblatt would demand an urgent turnaround in the firm’s cost or revenue drivers.
68.39%
Net income/share CAGR at 75-90% of AGEN's 89.46%. Bill Ackman would press for strategic moves to boost long-term earnings.
68.39%
5Y net income/share CAGR at 75-90% of AGEN's 82.14%. Bill Ackman would advocate improvements to match competitor’s profit expansion.
65.23%
Positive short-term CAGR while AGEN is negative. John Neff would see a clear advantage in near-term profit trajectory.
-358.21%
Both are negative. Martin Whitman suspects the segment is in decline or saddled with persistent unprofitability or write-downs.
-358.21%
Negative 5Y equity/share growth while AGEN is at 48.03%. Joel Greenblatt sees the competitor building net worth while this firm loses ground.
-14.02%
Negative 3Y equity/share growth while AGEN is at 45.28%. Joel Greenblatt demands an urgent fix in capital structure or profitability vs. the competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-3.24%
Both erode book value/share. Martin Whitman suspects a difficult environment or poor capital deployment for both players.
8.21%
Debt growth far above AGEN's 5.81%. Michael Burry fears the firm is taking on undue leverage vs. the competitor.
No Data
No Data available this quarter, please select a different quarter.
-39.30%
We cut SG&A while AGEN invests at 5.57%. Joel Greenblatt sees a short-term margin benefit but wonders if the competitor invests for future gains.